Wednesday, 22 November 2017
Latest news
Main » Price Target Analysis Valeant Pharmaceuticals International, Inc. (VRX)

Price Target Analysis Valeant Pharmaceuticals International, Inc. (VRX)

14 September 2017

The SI to Genie Energy Limited's float is 4.19%. About 3.84M shares traded. Verisign, Inc. (NASDAQ:VRSN) has risen 7.59% since September 14, 2016 and is uptrending. It has outperformed by 23.57% the S&P500.

Nomura Asset Management Company Ltd decreased Verisign Inc (VRSN) stake by 50.64% reported in 2016Q4 SEC filing. Its last month's stock price volatility remained 2.9% which for the week stands at 3.64%. PNC Financial Services Group Inc. now owns 10,965 shares of the specialty pharmaceutical company's stock valued at $121,000 after buying an additional 2,763 shares in the last quarter.

Vetr downgraded shares of Valeant Pharmaceuticals International, Inc.

The company surged 1.69% and closed its last trading session at $14.19. The target implies a 10.85% spike from where the shares are now trading. The legal version of this story can be accessed at https://weekherald.com/2017/09/14/cibc-world-markets-inc-acquires-83592-shares-of-valeant-pharmaceuticals-international-inc-vrx.html. It has underperformed by 65.21% the S&P500. Fosun Int holds 3.6% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) or 1.85 million shares. On average, analysts predict that Valeant Pharmaceuticals International will post $3.89 earnings per share for the current fiscal year. The company's 50-day moving average price is $18.34 and its 200 day moving average price is $17.22. During the same quarter in the previous year, the business earned ($0.88) earnings per share.

Investors sentiment decreased to 1.08 in 2016 Q4. Its up 0.08, from 1.19 in 2016Q3. It turned negative, as 82 investors sold VRX shares while 87 reduced holdings.

Institutional ownership refers to the ownership stake in a company that is held by large financial organizations, pension funds or endowments. 193.03 million shares or 13.22% less from 222.43 million shares in 2016Q3 were reported. Sg Americas Ltd Liability accumulated 69,801 shares. Benjamin F Edwards And has 99 shares for 0% of their portfolio. State Street stated it has 32.32M shares or 0.01% of all its holdings. Jefferies Grp Incorporated Limited holds 0.01% or 98,574 shares.

07/12/2017 - Valeant Pharmaceuticals International, Inc. had its "underweight" rating reiterated by analysts at Piper Jaffray. Wells Fargo & Company Mn holds 0% of its portfolio in DCP Midstream LP (NYSE:DCP) for 123,978 shares. Private stated it has 0.56% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX).

Valeant Pharmaceuticals International, is a pharmaceutical and medical device company. 1,096 were accumulated by Highstreet Asset. Kayne Anderson Rudnick Invest Mgmt Limited Liability Co has invested 0.05% in Amgen, Inc. (NYSE:VRX) (TSE:VRX) in a research note released on Thursday.

ILLEGAL ACTIVITY WARNING: "Valeant Pharmaceuticals International, Inc". Moreover, First Foundation Advsrs has 0.01% invested in Valeant Pharmaceuticals Intl Inc (NYSE:VRX).

Since March 14, 2017, it had 1 insider buy, and 0 sales for $278,000 activity. Another trade for 3.00M shares valued at $32.47M was made by ValueAct Holdings - L.P. on Tuesday, March 14. Acadian Asset Management LLC now owns 425,100 shares of the specialty pharmaceutical company's stock worth $10,411,000 after buying an additional 238,216 shares during the last quarter. The insider DE SCHUTTER RICHARD U bought $278,000.

More notable recent Valeant Pharmaceuticals Intl Inc (NYSE:VRX) news were published by: Investorplace.com which released: "Why Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Higher Today" on August 17, 2017, also Seekingalpha.com with their article: "Has Valeant Run Out Of Catalysts?" published on September 12, 2017, Gurufocus.com published: "Chou RRSP Fund Buys Valeant Pharmaceuticals International Inc, EXCO Resources ..." on September 12, 2017. Therefore 22% are positive. According to these analysts, the Low Revenue Estimate for Valeant Pharmaceuticals International, Inc.is 270.8 Million and the High Revenue Estimate is 333 Million. Royal Bank Of Canada restated a sector perform rating and set a $19.00 price objective (up from $18.00) on shares of Valeant Pharmaceuticals International in a research report on Wednesday, May 10th. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has "Market Perform" rating given on Wednesday, June 29 by BMO Capital Markets. Qs Ltd reported 0% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). The stock has "Buy" rating by Stifel Nicolaus on Thursday, January 5. The rating was maintained by Deutsche Bank on Tuesday, October 20 with "Hold". The stock has "Equal-Weight" rating by Morgan Stanley on Friday, October 2.

Cypress Funds Llc increased Skyworks Solutions Inc (NASDAQ:SWKS) stake by 12,500 shares to 110,000 valued at $8.21M in 2016Q4. 561.98 million shares or 1.23% less from 568.98 million shares in 2016Q3 were reported. Walgreens Boots Alliance Inc was raised too.

Bellerophon Therapeutics, Inc.is a clinical-stage therapeutics company. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. It now has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for with MarketBeat.com's FREE daily email newsletter.